Bionano Genomics Announces Closing of $101.8 Million Underwritten Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Bionano Genomics, Inc. (BNGO) has successfully closed its underwritten public offering of 33,368,851 shares at $3.05 per share, raising approximately $101.8 million in gross proceeds. This offering includes the full exercise of the underwriters' option to purchase 4,352,458 additional shares. The shares were offered under a previously filed shelf registration statement and are designed to support Bionano's genome analysis services and products.
- Raised approximately $101.8 million in gross proceeds through the public offering.
- The funds will support Bionano's growth in genome analysis tools and services.
- Issuing a large number of shares may lead to shareholder dilution.
SAN DIEGO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- BIONANO GENOMICS, INC. (Nasdaq: BNGO), announced today the closing of its previously announced underwritten public offering of 33,368,851 shares of its common stock, including 4,352,458 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares, at a price to the public of
Oppenheimer & Co. Inc. acted as the sole book-running manager for the offering. BTIG, LLC acted as the lead manager, and Ladenburg Thalmann & Co. Inc. and Maxim Group LLC acted as the co-managers.
The shares were offered pursuant to a "shelf" registration statement on Form S-3 (File No. 333-245762) previously filed on August 14, 2020 and declared effective by the Securities and Exchange Commission (SEC) on August 25, 2020. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the website of the SEC at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering may be obtained from: Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, New York 10004, by telephone at 212-667-8055, or by email at EquityProspectus@opco.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Bionano Genomics
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 (617) 430-7577
arr@lifesciadvisors.com
FAQ
What was the price of Bionano Genomics' recent stock offering?
How much capital did Bionano Genomics raise from the offering?
How many shares did Bionano Genomics offer in the public offering?
Who managed the public offering for Bionano Genomics?
Will Bionano Genomics' stock face dilution after the offering?
